Eu­rope lines up first CRISPR ther­a­py ap­proval

Fol­low­ing FDA ap­proval, Ver­tex Phar­ma­ceu­ti­cals and CRISPR Ther­a­peu­tics on Fri­day re­ceived a pos­i­tive rec­om­men­da­tion for a con­di­tion­al ap­proval by a key Eu­ro­pean med­i­cines pan­el for the two com­pa­nies’ Cas­gevy, the first treat­ment that us­es CRISPR-based gene edit­ing tech­nol­o­gy.

The EMA’s Com­mit­tee for Med­i­c­i­nal Prod­ucts for Hu­man Use rec­om­mend­ed that Cas­gevy re­ceive a con­di­tion­al ap­proval dur­ing its De­cem­ber meet­ing held Mon­day through Thurs­day. The rec­om­men­da­tion comes af­ter Cas­gevy won FDA ap­proval last week, mark­ing a ma­jor mile­stone in treat­ing sick­le cell dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER